NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines

Novavax (NVAX) announced that it has started dosing participants in the phase III study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.The study will compare the immunogenicity and safety of the CIC vaccine with separate administrations of Novavax’s currently authorized COVID-19 vaccine and a licensed seasonal influenza vaccine. Management will also assess the immunogenicity and safety of its standalone influenza vaccine.Both experimental vaccin ...